MA39448A1 - (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical - Google Patents

(r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Info

Publication number
MA39448A1
MA39448A1 MA39448A MA39448A MA39448A1 MA 39448 A1 MA39448 A1 MA 39448A1 MA 39448 A MA39448 A MA 39448A MA 39448 A MA39448 A MA 39448A MA 39448 A1 MA39448 A1 MA 39448A1
Authority
MA
Morocco
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medical use
pain
Prior art date
Application number
MA39448A
Other languages
English (en)
Other versions
MA39448B1 (fr
Inventor
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
Filipe Augusto Eusébio Pardal
João Carlos Ramos Damil
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA39448A1 publication Critical patent/MA39448A1/fr
Publication of MA39448B1 publication Critical patent/MA39448B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

L'invention concerne le (r)-pirlindole ou ses sels pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques les comprenant pour un usage dans le traitement thérapeutique et la prévention de la douleur.
MA39448A 2014-05-09 2014-05-09 (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical MA39448B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (fr) 2014-05-09 2014-05-09 (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Publications (2)

Publication Number Publication Date
MA39448A1 true MA39448A1 (fr) 2018-08-31
MA39448B1 MA39448B1 (fr) 2019-12-31

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39448A MA39448B1 (fr) 2014-05-09 2014-05-09 (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Country Status (28)

Country Link
US (2) US20170145015A1 (fr)
EP (1) EP3054950B1 (fr)
JP (1) JP2017514884A (fr)
KR (1) KR102232198B1 (fr)
CN (1) CN106413714A (fr)
AU (1) AU2014393489B2 (fr)
CA (1) CA2948596C (fr)
CY (1) CY1119522T1 (fr)
DK (1) DK3054950T3 (fr)
EC (1) ECSP16086232A (fr)
ES (1) ES2649491T3 (fr)
HR (1) HRP20171650T1 (fr)
HU (1) HUE035030T2 (fr)
IL (1) IL248854B (fr)
LT (1) LT3054950T (fr)
MA (1) MA39448B1 (fr)
MX (1) MX368735B (fr)
NO (1) NO3054950T3 (fr)
NZ (1) NZ726131A (fr)
PH (1) PH12016502236A1 (fr)
PL (1) PL3054950T3 (fr)
PT (1) PT3054950T (fr)
RS (1) RS56590B1 (fr)
RU (1) RU2695607C2 (fr)
SI (1) SI3054950T1 (fr)
TN (1) TN2016000497A1 (fr)
UA (1) UA116499C2 (fr)
WO (1) WO2015171004A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413714A (zh) 2014-05-09 2017-02-15 特克尼梅德医疗技术股份公司 (r)‑吡吲哚及其药学上可接受的盐的药学用途
TN2016000495A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine.
KR102421013B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
WO2019241564A1 (fr) * 2018-06-13 2019-12-19 Children's Medical Center Corporation Biomarqueurs de douleur neuropathique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
JP2006525226A (ja) * 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
EP1663180A1 (fr) * 2003-09-15 2006-06-07 Vectura Limited Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
US9814712B2 (en) * 2014-05-09 2017-11-14 Tecnimede Sociedade Tecnico-Medicinal S.A. (S)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CN106413714A (zh) 2014-05-09 2017-02-15 特克尼梅德医疗技术股份公司 (r)‑吡吲哚及其药学上可接受的盐的药学用途
TN2016000495A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine.

Also Published As

Publication number Publication date
AU2014393489B2 (en) 2020-01-02
NZ726131A (en) 2018-12-21
HUE035030T2 (en) 2018-05-02
CA2948596C (fr) 2021-06-08
MX2016014701A (es) 2017-05-23
EP3054950A1 (fr) 2016-08-17
KR102232198B1 (ko) 2021-03-26
RU2016148182A (ru) 2018-06-13
RU2695607C2 (ru) 2019-07-24
MX368735B (es) 2019-10-14
LT3054950T (lt) 2017-11-27
HRP20171650T1 (hr) 2017-12-15
CY1119522T1 (el) 2018-03-07
US20170145015A1 (en) 2017-05-25
PL3054950T3 (pl) 2018-02-28
TN2016000497A1 (en) 2018-04-04
EP3054950B1 (fr) 2017-08-02
KR20170003567A (ko) 2017-01-09
SI3054950T1 (sl) 2017-12-29
AU2014393489A1 (en) 2016-11-24
US20180111944A1 (en) 2018-04-26
RS56590B1 (sr) 2018-02-28
WO2015171004A1 (fr) 2015-11-12
DK3054950T3 (en) 2017-11-06
MA39448B1 (fr) 2019-12-31
US10533012B2 (en) 2020-01-14
CN106413714A (zh) 2017-02-15
ECSP16086232A (es) 2017-02-24
JP2017514884A (ja) 2017-06-08
PT3054950T (pt) 2017-11-29
IL248854A0 (en) 2017-01-31
CA2948596A1 (fr) 2015-11-12
IL248854B (en) 2020-05-31
PH12016502236A1 (en) 2017-02-06
NO3054950T3 (fr) 2017-12-30
UA116499C2 (uk) 2018-03-26
ES2649491T3 (es) 2018-01-12
RU2016148182A3 (fr) 2018-06-13

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
IN2015DN00376A (fr)
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
PH12016502352A1 (en) Pharmaceutical composition
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
PH12016502353A1 (en) Pharmaceutical composition
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2015165964A8 (fr) Traitement et prévention de la maladie d'alzheimer
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
TH167851B (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
TH168999A (th) สารยับยั้งของ rorc2 ประเภทเฮเทอโรไบไซโคลแอริล และวิธีการใช้ของมัน
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค